ライフサイエンスコーパス: varicella zoster

1 and pneumonia, and an increase observed for varicella zoster.

2 prophylaxis against Pneumocystis carinii and varicella zoster.

3 -mg dose of fingolimod: disseminated primary varicella zoster and herpes simplex encephalitis.

4 varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, a

5 bacterial and viral (due to herpes simplex, varicella zoster, and enteroviruses) meningitis/encephal

6 smosis, other infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus,

7 reaction (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus an

8 Prophylaxis with varicella-zoster immunoglobulin can reduce the severity

9 number and critical immunization coverage of varicella-zoster infection in Belgium, Italy, Poland, an

10 virus (OPV), rubella, measles, yellow fever, varicella-zoster, multivalent measles/mumps/rubella, and

11 of herpes zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological me

12 roidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoi

13 clonal expansions in response to attenuated varicella-zoster vaccination in four pairs of adult iden

14 laria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III).

15 Two doses of live-attenuated varicella-zoster vaccine are recommended for human immun

16 thy, such as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thy

17 e calculated an anterograde velocity for the varicella zoster virion of 5.55 mm/h or .0015 mm/s.

18 megalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), h

19 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

20 s HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytome

21 tients showed a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV

22 Varicella zoster virus (VZV) and the two herpes simplex

23 Varicella zoster virus (VZV) antibody titers (measured b

24 Varicella zoster virus (VZV) antigen was found in all of

25 Vasculopathies caused by varicella zoster virus (VZV) are indicative of a product

26 CMV and varicella zoster virus (VZV) are significant causes of m

27 response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzym

28 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

29 se of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a

30 , or no history of zoster (group 3) revealed varicella zoster virus (VZV) DNA in saliva samples from

31 rs who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inocul

32 Varicella zoster virus (VZV) establishes latency in dors

33 Varicella zoster virus (VZV) establishes lifelong persis

34 as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further char

35 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

36 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

37 Reactivation of the varicella zoster virus (VZV) increases during aging.

38 Varicella zoster virus (VZV) infections are a relevant c

39 virus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored i

40 Varicella zoster virus (VZV) is a neurotropic alphaherpe

41 Varicella zoster virus (VZV) is a skin-tropic virus that

42 As) from patients with giant cell arteritis, varicella zoster virus (VZV) is seen in perineurial cell

43 Varicella zoster virus (VZV) is the causative agent of c

44 Varicella Zoster Virus (VZV) is the causative agent of v

45 Varicella zoster virus (VZV) is the etiological agent of

46 s" postulates that reexposure to circulating varicella zoster virus (VZV) over the life span inhibits

47 Varicella zoster virus (VZV) reactivation results in zos

48 An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being de

49 zoster (HZ) cases may play a larger role in varicella zoster virus (VZV) transmission.

50 Varicella zoster virus (VZV) typically causes chickenpox

51 ne responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), w

52 te the efficacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster p

53 Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has b

54 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

55 lovirus (CMV), Epstein-Barr virus (EBV), and varicella zoster virus (VZV) was determined in crewmembe

56 IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline a

57 cytomegalovirus, herpes simplex virus (HSV), varicella zoster virus (VZV), and rubella.

58 portion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive pred

59 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

60 d were hepatitis A (HAV), hepatitis B (HBV), varicella zoster virus (VZV), measles, and mumps.

61 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

62 erpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accum

63 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

64 Boost of varicella zoster virus (VZV)-specific cellular immunity

65 We investigated the relationship between varicella zoster virus (VZV)-specific memory CD4(+) T ce

66 virus type 1 (HSV-1) and type 2 (HSV-2) and varicella zoster virus (VZV)-was determined in autonomic

67 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

68 ompromised individuals after reactivation of varicella zoster virus (VZV).

69 n pathogens herpes simplex viruses (HSV) and varicella zoster virus (VZV).

70 ses with age, which leads to reactivation of varicella zoster virus (VZV).

71 CF; human cytomegalovirus (HCMV) 11% in GCF; varicella zoster virus 6% in saliva and 3% in GCF; of hu

72 ytomegalovirus [CMV], herpes simplex I/II or varicella zoster virus [HSV/VZV], blood stream infection

73 For herpes simplex virus, varicella zoster virus and cytomegalovirus, these advanc

74 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

75 genes of both herpes simplex virus (HSV) and varicella zoster virus and functions, in part, by coupli

76 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

77 ld decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of

78 (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction)

79 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

80 Varicella zoster virus DNA was detected 2 months after t

81 Varicella zoster virus encephalitis was infrequent follo

82 Varicella zoster virus encodes an immediate-early (IE) p

83 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

84 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

85 contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, a

86 processes, including ubiquitin clearance and Varicella Zoster Virus infection.

87 nd increased susceptibility to bacterial and varicella zoster virus infections.

88 One patient with varicella zoster virus meningitis and acute GVHD had iC9

89 e fills a notable gap in our knowledge about varicella zoster virus neuronal transportation.

90 derate quality showed an association between varicella zoster virus reactivation (ophthalmic zoster)

91 Because there is no good animal model of varicella zoster virus reactivation from latency, this e

92 ion (PCR) for herpes simplex virus (HSV) and varicella zoster virus was done in 237 (69%) and 82 (24%

93 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

94 ty of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our po

95 Herpes simplex virus, varicella zoster virus, and pseudorabies virus are neuro

96 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

97 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

98 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

99 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

100 deficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cy

101 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

102 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

103 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

104 nation that elicited an exceptionally strong varicella zoster virus-specific B-cell and CD8 T-cell re

105 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

106 erpes simplex virus and 8 patients (38%) had varicella zoster virus.

107 ese is also activated by the closely related varicella zoster virus.

108 ew mutations or recombination with wild-type Varicella zoster virus.

109 1), P. jirovecii pneumonia (1.77; .42-7.47), varicella-zoster virus (1.51; .71-3.22), as well as over

110 d 9 with herpes simplex virus (8.8%), 5 with varicella-zoster virus (4.9%), 27 with cytomegalovirus (

111 Varicella-zoster virus (VZV) activates the phosphatidyli

112 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

113 are the main architectural contrasts between varicella-zoster virus (VZV) and herpes simplex virus (H

114 d the Us9 homologs from two human pathogens, varicella-zoster virus (VZV) and herpes simplex virus ty

115 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

116 The herpesviruses varicella-zoster virus (VZV) and human cytomegalovirus (

117 herpes simpex virus 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV) and human herpesvirus 8 (HH

118 reactivation of herpesviruses, most commonly varicella-zoster virus (VZV) and pseudorabies virus (PRV

119 simplex virus type 1 (HSV-1) is conserved in varicella-zoster virus (VZV) and pseudorabies virus (PRV

120 ype 1 (EHV-1), pseudorabies virus (PRV), and varicella-zoster virus (VZV) and their subsequent functi

121 Infections with varicella-zoster virus (VZV) are associated with a range

122 gument proteins encoded by ORF11 and ORF9 of varicella-zoster virus (VZV) are conserved among all alp

123 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

124 y, IDE has been proposed as the receptor for varicella-zoster virus (VZV) attachment.

125 Varicella-zoster virus (VZV) causes chicken pox and shin

126 Varicella-zoster virus (VZV) causes chickenpox and react

127 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

128 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

129 Varicella-zoster virus (VZV) causes chickenpox upon prim

130 ies for treatment of VZV diseases.IMPORTANCE Varicella-zoster virus (VZV) causes herpes zoster, a maj

131 Varicella-zoster virus (VZV) causes varicella and establ

132 Varicella-zoster virus (VZV) characteristically forms mu

133 We studied a patient with varicella-zoster virus (VZV) CNS vasculopathy and as par

134 y throughout the study and were analyzed for varicella-zoster virus (VZV) DNA by use of both qualitat

135 In this report, we investigated varicella-zoster virus (VZV) egress in a cell line from

136 Herein we describe an episode of focal varicella-zoster virus (VZV) encephalitis in a healthy y

137 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

138 Varicella-zoster virus (VZV) establishes latency in huma

139 Varicella-zoster virus (VZV) establishes lifelong neuron

140 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

141 When grown in cultured cells, varicella-zoster virus (VZV) forms many aberrant light p

142 Information about varicella-zoster virus (VZV) gB is limited, but homology

143 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

144 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

145 (EBV) EB2, herpes simplex virus (HSV) ICP27, varicella-zoster virus (VZV) IE4/ORF4, and cytomegalovir

146 The varicella-zoster virus (VZV) IE62 protein is the major t

147 nses in the bone marrow.IMPORTANCE Childhood varicella-zoster virus (VZV) immunization induces immune

148 ects immediate-early protein IE63 encoded by varicella-zoster virus (VZV) in the cytoplasm of product

149 sensitivity to detect antibody responses to varicella-zoster virus (VZV) in vaccinated individuals,

150 Varicella-zoster virus (VZV) induces apoptosis in human

151 Previous studies have demonstrated that varicella-zoster virus (VZV) infection activates ERK1/2,

152 Varicella-zoster virus (VZV) infection causes varicella,

153 Primary varicella-zoster virus (VZV) infection in humans produce

154 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

155 acaques (RMs) recapitulates the hallmarks of varicella-zoster virus (VZV) infection of humans, includ

156 Varicella-zoster virus (VZV) infection provides a valuab

157 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

158 ent infant with concurrent primary wild-type varicella-zoster virus (VZV) infection, in whom chickenp

159 Varicella-zoster virus (VZV) infections increasingly are

160 Varicella-zoster virus (VZV) is a common pathogen that c

161 Varicella-zoster virus (VZV) is a highly contagious agen

162 Varicella-zoster virus (VZV) is a highly neurotropic vir

163 Varicella-zoster virus (VZV) is a human alpha-herpesviru

164 Varicella-zoster virus (VZV) is a human alphaherpesvirus

165 Varicella-zoster virus (VZV) is a human neurotropic alph

166 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

167 Varicella-zoster virus (VZV) is a medically important hu

168 Varicella-zoster virus (VZV) is a neurotropic alphaherpe

169 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

170 Varicella-zoster virus (VZV) is a ubiquitous, highly cel

171 Varicella-zoster virus (VZV) is an alphaherpesvirus that

172 Varicella-zoster virus (VZV) is an alphaherpesvirus that

173 Varicella-zoster virus (VZV) is an alphaherpesvirus that

174 Varicella-zoster virus (VZV) is an alphaherpesvirus that

175 Varicella-zoster virus (VZV) is an extremely cell-associ

176 e major immediate early 62 (IE62) protein of varicella-zoster virus (VZV) is delivered to newly infec

177 Varicella-zoster virus (VZV) is highly cell associated w

178 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

179 Varicella-zoster virus (VZV) is one of the most common a

180 Varicella-zoster virus (VZV) is renowned for its low tit

181 Varicella-zoster virus (VZV) is the alphaherpesvirus tha

182 Varicella-zoster virus (VZV) is the causative agent of b

183 Varicella-zoster virus (VZV) is the causative agent of c

184 Varicella-zoster virus (VZV) is the etiological agent of

185 Varicella-zoster virus (VZV) is under consideration as a

186 We report a case of AIDS presenting as varicella-zoster virus (VZV) meningomyeloradiculitis ass

187 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

188 Varicella-zoster virus (VZV) open reading frame (ORF) 63

189 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

190 Varicella-zoster virus (VZV) open reading frame 61 (ORF6

191 Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF6

192 f transcripts corresponding to all 68 unique varicella-zoster virus (VZV) open reading frames (ORFs)

193 The varicella-zoster virus (VZV) ORF61 protein is necessary

194 The architecture of the varicella-zoster virus (VZV) origin of DNA replication (

195 In this report, we show that ORF61p, the varicella-zoster virus (VZV) ortholog of ICP0, does not

196 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

197 this minireview is to provide an overview of varicella-zoster virus (VZV) phylogenetics and phylogeog

198 Analyses of varicella-zoster virus (VZV) protein expression during l

199 ORF66p, a virion-associated varicella-zoster virus (VZV) protein, is a member of a c

200 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

201 Varicella-zoster virus (VZV) T-cell responses by interfe

202 Varicella-zoster virus (VZV) T-cell-mediated immunity (V

203 The varicella-zoster virus (VZV) terminase components (pORF2

204 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

205 Studies of varicella-zoster virus (VZV) tropism for T cells support

206 Varicella-zoster virus (VZV) vaccine appears to be safe

207 Although a varicella-zoster virus (VZV) vaccine has been used for m

208 ldhood immunization with the live-attenuated varicella-zoster virus (VZV) vaccine induces protective

209 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

210 Varicella-zoster virus (VZV) vasculopathy produces strok

211 ent of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).

212 Varicella-zoster virus (VZV), a double-stranded DNA alph

213 igated during the entire infectious cycle of varicella-zoster virus (VZV), a human herpesvirus.

214 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

215 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

216 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

217 1) and pseudorabies virus (PRV) and ORF66 in varicella-zoster virus (VZV), affects several viral and

218 Here we report that varicella-zoster virus (VZV), an alphaherpesvirus that i

219 pear healthy at 2 weeks after infection with varicella-zoster virus (VZV), and the cell culture mediu

220 ovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).

221 sviruses, herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), confirmed the expression o

222 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

223 icella virus (SVV), the counterpart of human varicella-zoster virus (VZV), developed primary infectio

224 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

225 ing the medically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virio

226 Varicella-zoster virus (VZV), of the family Alphaherpesv

227 showed cytopathic changes, but HSV-1, unlike varicella-zoster virus (VZV), only rarely infected satel

228 Like varicella-zoster virus (VZV), simian varicella virus (SV

229 Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyl

230 In varicella-zoster virus (VZV)-infected primary human brai

231 the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-

232 Varicella-zoster virus (VZV)-specific cell-mediated immu

233 To measure varicella-zoster virus (VZV)-specific immune responses u

234 ssays and flow cytometry, we determined that varicella-zoster virus (VZV)-specific peak T helper 1 (V

235 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

236 rus (CMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV).

237 rpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).

238 ly recognized component of the life cycle of varicella-zoster virus (VZV).

239 lication that can occur with reactivation of varicella-zoster virus (VZV).

240 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

241 Our work has shown that varicella-zoster virus (VZV; also called human herpesvir

242 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

243 nate gene activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspe

244 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

245 virus 1 [HSV-1], HSV-2, JC virus [JCV], and varicella-zoster virus [VZV]).

246 cropsy of two monkeys inoculated with simian varicella-zoster virus and euthanized 117 days later.

247 y, other human-restricted viruses.IMPORTANCE Varicella-zoster virus and human cytomegalovirus infect

248 ia in adults includes common agents, such as varicella-zoster virus and influenza virus, as well as r

249 finding associated with uveitis secondary to varicella-zoster virus and Toxoplasma gondii coinfection

250 s of anterior uveitis in his left eye due to varicella-zoster virus and Toxoplasma gondii coinfection

251 Varicella-zoster virus antigen was found in 45 of 70 GCA

252 Varicella-zoster virus antigen was frequently found in p

253 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

254 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

255 clonal antibodies against a major antigen of varicella-zoster virus called gE.

256 MPORTANCE Herpes simplex viruses 1 and 2 and varicella-zoster virus cause significant morbidity and m

257 We compared varicella-zoster virus cell-mediated immunity (VZV-CMI)

258 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

259 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

260 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

261 rpes zoster is a common late complication of varicella-zoster virus exposure and can be further compl

262 hus, a 30-h delay after death did not affect varicella-zoster virus expression in latently infected g

263 Studies of varicella-zoster virus gene expression during latency re

264 The varicella-zoster virus geometric mean titer (GMT) and ge

265 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

266 An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vacci

267 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

268 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

269 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

270 ogic modulators restores immune responses to varicella-zoster virus in vaccinees.

271 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

272 erties that may favor reactivation of latent varicella-zoster virus infection.

273 While varicella-zoster virus is also insensitive to interferon

274 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

275 Because features of varicella-zoster virus latency are similar in primate an

276 The varicella-zoster virus major transactivator, IE62, conta

277 Available varicella-zoster virus models can be classified in 3 mai

278 ilar function in human herpesviruses such as varicella-zoster virus or herpes simplex viruses.

279 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

280 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

281 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

282 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

283 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.

284 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

285 Findings from skin biopsy, viral culture for varicella-zoster virus, and skin prick test to common fo

286 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

287 ZVL and, together with baseline immunity to varicella-zoster virus, explains the effect of age on th

288 erritin levels were highest in patients with varicella-zoster virus, hepatitis, or malaria (median, 1

289 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

290 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

291 in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to va

292 1, CTLA-4, and TIM-3, whereas <2% of CMV- or varicella-zoster virus-specific CD4(+) T cells expressed

293 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

294 losely related to herpes simplex viruses and varicella-zoster virus.

295 G synthesis, and elevated antibody titers to varicella-zoster virus.

296 d, for example, in relation to pertussis and varicella-zoster virus.

297 pathogens herpes simplex viruses 1 and 2 and varicella-zoster virus.

298 ation were detected in OPV, mumps virus, and varicella-zoster virus.

299 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) may cause severe infecti

300 Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common conditi